Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Why this ASX biotech is primed to capitalise as big pharma flocks to the rare diseases market
News
In Case You Missed It: High grade antimony and sneaky takeover attempts
Health & Biotech
PharmAust eyes US orphan drug designation after successful phase 1 motor neurone disease trial
News
In Case You Missed It: Abundant spodumene crystals and solid Q3 gold production
Health & Biotech
PharmAust races for access to the US market after confirming its canine cancer treatment is safe for pooches
Health & Biotech
New CEO to take the helm as PharmAust progresses clinical studies
Health & Biotech
Results from 11 out of 12 patients in PharmAust trial point to stabilised MND progression
News
Top 10 at 10: Red Sky jumps 20pc on news of 100pc offtake deal with Viva
Health & Biotech
Preliminary evidence for MPL activity enables PharmAust to commence planning a Phase 2 trial in motor neurone disease
Health & Biotech
PharmAust MPL is well tolerated in three MND/ALS patient cohorts
Health & Biotech
PharmAust nears end point of its Phase 2 dog cancer trial and the outlook seems sunny
News
In Case You Missed It: A management shuffle, lithium and some rare earths
Health & Biotech
PharmAust secures more proof of MPL’s efficacy in stopping MND progression
Health & Biotech
Louie the Beagle has lived comfortably with cancer for the past year, thanks to PharmAust
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
PharmAust’s preliminary trial data indicate slowing or stopping the progression of motor neuron loss that causes MND
News
